Cellular, Molecular and Biomedical Reports

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Publication Ethics and Malpractice Statement

Ethical Oversight

Research Data Sharing Policies

Assignment - CC BY

Repository policy

Publisher’S Note

Publisher Business Model

Processing Cycle

Informed Consent

Guiding Principles for Research Involving Animals and Human Beings

Open Access Policy

Copyright and license

Compliance with Ethical Standards

CrossMark Policy

Journal Metrics

FAQ

News

Related Links

Editors

Editorial Policies (Appeals and Complaints)

Guidelines for Guest Editors

Web of Science Profile (for Editing)

Reviewers

Peer Review Process

Peer Review Policy

Web of Science Profile (for reviewing)

Instructions for Authors

Plagiarism and Similarity Rates

Permanency of Articles

Journal's policy on data fabrication

Article Processing Charges

Publication Fee

Authors Benefits

Practical Guide to the SI Units

Polycystic Ovary Syndrome: pathogenesis, management, and treatment with metals and organic compounds

Document Type : Review Article

Authors

Remote Sensing Department, College of Remote Sensing and Geophysics, Al-Karkh University of Science, Baghdad, Iraq

Abstract

Polycystic ovary syndrome (PCOS) is a popular illness in women after puberty age. It’s described via overdone androgen production, and ovulation unrest while elevating metabolic syndrome. PCOS was usually diagnosed by Ultrasound or blood test to check the androgens and other hormone levels. There are many causes of having pathogenesis of POCS which was related to abnormalities in hormone levels, insulin resistance, obesity, and others. the symptoms of PCOS could include irregular periods, excess body hair, weight gain, oily skin, and infertility. Due to the variety of symptoms, the POCS has many different types of treatment options, for instant use of medications or lifestyle changes such as weight loss. Many medications are used to treat PCOS like organic compounds and have proven effective in treating PCOS as well as many metallic elements will aid medicinal chemists in planning, organizing, and implementing new approaches toward the discovery of novel drugs. One of the most important medications which were used to treat PCOS is clomiphene citrate and that is commonly used for the treatment of infertility. This review highlights to the causes and treatments of PCOS and gives many examples of recent research that uses drugs and metallic elements as a medication.

Graphical Abstract

Polycystic Ovary Syndrome: pathogenesis, management, and treatment with metals and organic compounds

Keywords

Main Subjects

Full Text

Selected author of this article by journal

ِ
Dr. Shimaa Ahmad Hassan
Al-Karkh University of Science

ORCID

Scopus

WOS

Google scholar

Open Access

This article is licensed under a CC BY License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/

 

Publisher’s Note

CMBR journal remains neutral with regard to jurisdictional claims in published maps and institutional afflictions.

 

Letters to Editor

Given that CMBR Journal's policy in accepting articles will be strict and will do its best to ensure that in addition to having the highest quality published articles, the published articles should have the least similarity (maximum 18%). Also, all the figures and tables in the article must be original and the copyright permission of images must be prepared by authors. However, some articles may have flaws and have passed the journal filter, which dear authors may find fault with. Therefore, the editor of the journal asks the authors, if they see an error in the published articles of the journal, to email the article information along with the documents to the journal office.

CMBR Journal welcomes letters to the editor ([email protected]) for the post-publication discussions and corrections which allows debate post publication on its site, through the Letters to Editor. Critical letters can be sent to the journal editor as soon as the article is online. Following points are to be considering before sending the letters (comments) to the editor.


[1] Letters that include statements of statistics, facts, research, or theories should include appropriate references, although more than three are discouraged.
[2] Letters that are personal attacks on an author rather than thoughtful criticism of the author’s ideas will not be considered for publication.
[3] There is no limit to the number of words in a letter.
[4] Letter writers should include a statement at the beginning of the letter stating that it is being submitted either for publication or not.

[5] Anonymous letters will not be considered.
[6] Letter writers must include Name, Email Address, Affiliation, mobile phone number, and Comments

[7] Letters will be answered as soon as possible

References
  1. Unfer V, Proietti S, Porcaro G, Gullo G, Carlomagno G, Bizzarri M (2014) Polycystic ovary syndrome: features, diagnostic criteria and treatments. Endocrinology & Metabolic Syndrome 3 (03): P.1000136. doi: https://doi.org/10.4172/2161-1017.1000136
  2. Suhas D, Suresh D, Panchshila D (2015) Review on Introduction to PCOS and their management. J Sci 5: 208-212. doi: https://doi.org/10.22159/ijcpr.2018v10i6.30969
  3. Balen AH, Tan S-L, MacDougall J, Jacobs HS (1993) Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Human Reproduction 8 (6): 959-964. doi: https://doi.org/10.1093/oxfordjournals.humrep.a138174
  4. Aslan K, Albayrak O, Orhaner A, Kasapoglu I, Uncu G (2022) Incidence of congenital uterine abnormalities in polycystic ovarian syndrome (CONUTA Study). European Journal of Obstetrics & Gynecology and Reproductive Biology 271: 183-188. doi: https://doi.org/10.1016/j.ejogrb.2022.02.012
  5. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK (2013) Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism 98 (12): 4565-4592. doi: https://doi.org/10.1210/jc.2013-2350
  6. Nagarathna P, Rajan PR, Koneri R (2014) A detailed study on poly cystic ovarian syndrome and it’s treatment with natural products. Int J Toxicol Pharmacol Res 5 (4): 109-120. doi: https://doi.org/10.22159/ijcpr.2018v10i6.30969.
  7. Kadam¹ R, Shinde K, Kadam R, MrudulaKulkarni DD (2021) Contemporary and Traditional Perspectives of Polycystic Ovarian Syndrome (PCOS): A Critical Review. IOSR Journal of Dental and Medical Sciences 13 (9): 88-98. doi: https://doi.org/10.9790/0853-13968998
  8. Li X, Feng Y, Lin J-F, Billig H, Shao R (2014) Endometrial progesterone resistance and PCOS. Journal of biomedical science 21: 1-7. doi: https://doi.org/10.1186/1423-0127-21-2
  9. Muhas C, Nishad K, Naseef P, Vajid KA (2021) An overview on polycystic ovary syndrome (PCOS). Technol Innov Pharm Res 6: 19-30. doi: https://doi.org/10.9734/bpi/tipr/v6/9810D
  10. Lujan ME, Chizen DR, Pierson RA (2008) Diagnostic Criteria for Polycystic Ovary Syndrome: Pitfalls and Controversies. Journal of Obstetrics and Gynaecology Canada 30 (8): 671-679. doi: https://doi.org/10.1016/S1701-2163(16)32915-2
  11. Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine reviews 33 (6): 981-1030. doi: https://doi.org/10.1210/er.2011-1034
  12. Azziz R (2018) Polycystic ovary syndrome. Obstetrics & Gynecology 132 (2): 321-336. doi: https://doi.org/10.1097/AOG.0000000000002698
  13. Polak K, Czyzyk A, Simoncini T, Meczekalski B (2017) New markers of insulin resistance in polycystic ovary syndrome. Journal of endocrinological investigation 40: 1-8. doi: https://doi.org/10.1007/s40618-016-0523-8
  14. Jeanes YM, Reeves S (2017) Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutrition research reviews 30 (1): 97-105. doi: https://doi.org/10.1017/S0954422416000287
  15. Li S, Huang X, Zhong H, Peng Q, Chen S, Xie Y, Qin X, Qin A (2014) Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis. Tumor Biology 35: 3961-3973. doi: https://doi.org/10.1007/s13277-013-1595-0
  16. Wild RA, Painter P, Coulson PB, CARRUTH KB, Ranney G (1985) Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 61 (5): 946-951. doi: https://doi.org/10.1210/jcem-61-5-946
  17. Carmina E, Rosato F, Janni A, Rizzo M, Longo R (2006) Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. The Journal of Clinical Endocrinology & Metabolism 91 (1): 2-6. doi: https://doi.org/10.1210/jc.2005-1457
  18. Fernandez RC, Moore VM, Van Ryswyk EM, Varcoe TJ, Rodgers RJ, March WA, Moran LJ, Avery JC, McEvoy RD, Davies MJ (2018) Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies. Nature and science of sleep 2018: 45-64. doi: https://doi.org/10.2147/NSS.S127475
  19. Rao MN, Neylan TC, Grunfeld C, Mulligan K, Schambelan M, Schwarz J-M (2015) Subchronic sleep restriction causes tissue-specific insulin resistance. The Journal of Clinical Endocrinology & Metabolism 100 (4): 1664-1671. doi: https://doi.org/10.1210/jc.2014-3911
  20. Dokras A, Bochner M, Hollinrake E, Markham S, VanVoorhis B, Jagasia DH (2005) Screening women with polycystic ovary syndrome for metabolic syndrome. Obstetrics & Gynecology 106 (1): 131-137. doi: https://doi.org/10.1097/01.AOG.0000167408.30893.6b
  21. Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M (2018) Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovascular diabetology 17 (1): 1-12. doi: https://doi.org/10.1186/s12933-018-0680-5
  22. Bhanpuri NH, Hallberg SJ, Williams PT, McKenzie AL, Ballard KD, Campbell WW, McCarter JP, Phinney SD, Volek JS (2018) Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. Cardiovascular diabetology 17: 1-16. doi: https://doi.org/10.1186/s12933-018-0698-8
  23. Damone AL, Joham AE, Loxton D, Earnest A, Teede HJ, Moran LJ (2019) Depression, anxiety and perceived stress in women with and without PCOS: a community-based study. Psychological medicine 49 (9): 1510-1520. doi: https://doi.org/10.1017/S0033291718002076
  24. Anonymous (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) (By: The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group). Human Reproduction 19 (1): 41-47. doi: https://doi.org/10.1093/humrep/deh098
  25. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human reproduction 33 (9): 1602-1618. doi: https://doi.org/10.1093/humrep/dey256
  26. Tasali E, Chapotot F, Leproult R, Whitmore H, Ehrmann DA (2011) Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 96 (2): 365-374. doi: https://doi.org/10.1210/jc.2010-1187
  27. Dumesic DA, Lobo RA (2013) Cancer risk and PCOS. Steroids 78 (8): 782-785. doi: https://doi.org/10.1016/j.steroids.2013.04.004
  28. Pasquali R, Antenucci D, Casimirri F, Venturoli S, Paradisi R, Fabbri R, Balestra V, Melchionda N, Barbara L (1989) Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. The Journal of Clinical Endocrinology & Metabolism 68 (1): 173-179. doi: https://doi.org/10.1210/jcem-68-1-173
  29. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G (2003) Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Human reproduction 18 (9): 1928-1932. doi: https://doi.org/10.1093/humrep/deg367
  30. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G (1999) Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. New England Journal of Medicine 340 (17): 1314-1320. doi: https://doi.org/10.1056/NEJM199904293401703
  31. Raval AD, Hunter T, Stuckey B, Hart RJ (2011) Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database of Systematic Reviews 2011 (10): 1-9. doi: https://doi.org/10.1002/14651858.CD008565.pub2
  32. Sepilian V, Nagamani M (2005) Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. The Journal of Clinical Endocrinology & Metabolism 90 (1): 60-65. doi: https://doi.org/10.1210/jc.2004-1376
  33. Helvaci N, Karabulut E, Demir AU, Yildiz BO (2017) Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature. Endocrine Connections 6 (7): 437-445. doi: https://doi.org/10.1530/EC-17-0129
  34. Gangale MF, Miele L, Lanzone A, Sagnella F, Martinez D, Tropea A, Moro F, Morciano A, Ciardulli A, Palla C (2011) Long‐term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clinical Endocrinology 75 (4): 520-527. doi: https://doi.org/10.1111/j.1365-2265.2011.04093.x
  35. Brown AJ, Tendler DA, McMurray RG, Setji TL (2005) Polycystic Ovary Syndrome and Severe Nonalcoholic Steatohepatitis: Beneficial Effect of Modest Weight Loss and Exercise on Liver Biopsy Findings. Endocrine Practice 11 (5): 319-324. doi: https://doi.org/10.4158/EP.11.5.319
  36. Greenwood EA, Pasch LA, Cedars MI, Legro RS, Huddleston HG (2018) Association among depression, symptom experience, and quality of life in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology 219 (3): 279.e271-279.e277. doi: https://doi.org/10.1016/j.ajog.2018.06.017
  37. Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R (2014) Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England Journal of Medicine 371 (2): 119-129. doi: https://doi.org/10.1056/NEJMoa1313517
  38. Kelly A, Jewelewicz R (1990) Alternate regimens for ovulation induction in polycystic ovarian disease. Fertility and Sterility 54 (2): 195-202. doi: https://doi.org/10.1016/s0015-0282(16)53688
  39. Tso LO, Costello MF, Albuquerque LET, Andriolo RB, Macedo CR (2020) Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2020 (12): 1-11. doi: https://doi.org/10.1002/14651858.CD006105.pub4
  40. Hassan SA, Lateef SM, Majeed IY (2020) Structural, Spectral and Thermal studies of new bidentate Schiff base ligand type (NO) derived from Mebendazol and 4-Aminoantipyrine and it's metal complexes and evaluation of their biological activity. Research Journal of Pharmacy and Technology 13 (6): 3001-3006. doi: http://dx.doi.org/10.5958/0974-360X.2020.00531.4
  41. Salloom HK, Lateef SM, Hassan SA (2020) Structural, Spectral and Thermal Studies of Novel Tridentate Schiff Base Ligand Type (NOO) as Donor Atoms Derived from Nalidixic Acid and 4-Aminoantipyrine and Metal Complexes and Evaluation of their Biological Activity. Journal of Global Pharma Technology 12 (2): 26-36. doi: https://doi.org/10.13140/RG.2.2.17525.12003
  42. Kumar P, Khan K (2012) Effects of metformin use in pregnant patients with polycystic ovary syndrome. Journal of human reproductive sciences 5 (2): 166. doi: https://doi.org/10.4103%2F0974-1208.101012
  43. Gayatri K, Kumar JS, Kumar BB (2010) Metformin and N-acetyl Cysteine in Polycystic Ovarian Syndrome–-A Comparative Study. Indian Journal of clinical medicine 1: 117739361000100002. doi: https://doi.org/10.1177/117739361000100002
  44. Lin M-W, Wu M-H (2015) The role of vitamin D in polycystic ovary syndrome. The Indian journal of medical research 142 (3): 238. doi: https://doi.org/10.4103%2F0971-5916.166527
  45. Hassan SA, Lateef SM (2021) Synthesis, structural, thermal and biological studies for new Schiff base derived from Isoniazid and it's complexes with metal ions. Egyptian Journal of Chemistry 64 (7): 3235-3243. doi: https://doi.org/10.21608/ejchem.2021.42643.2861
  46. Alwan TB, Jebur MH, Hassan SA (2023) Thermodynamic Studies Of Cu (II) complex of new bidentate Schiff base ligand type (NO) derived from Mebendazol. Egyptian Journal of Chemistry 66 (1): 563-572. doi: https://doi.org/10.21608/ejchem.2022.128827.5703
  47. Yin J, Hong X, Ma J, Bu Y, Liu R (2020) Serum trace elements in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Frontiers in endocrinology 11: 572384. doi: https://doi.org/10.3389/fendo.2020.572384
  48. Hassan SA, Hassan WF (2022) Structural and Spectral studies of new mixed Ligand complexes for 2-Amino-4-nitrophenol with some Metallic ions and Evaluation their Biological Activities. Research Journal of Pharmacy and Technology 15 (8): 3634-3640. doi: http://dx.doi.org/10.52711/0974-360X.2022.00608
  49. Pokorska-Niewiada K, Brodowska A, Brodowski J, Szczuko M (2022) Levels of trace elements in erythrocytes as endocrine disruptors in obese and nonobese women with polycystic ovary syndrome. International Journal of Environmental Research and Public Health 19 (2): 976. doi: https://doi.org/10.3390/ijerph19020976
  50. Hassan SA (2022) Synthesis and characterization of mixed ligand complexes from curcumin and new schiff base derived from isatin for some metallic ions and evaluation biological activities. Research Journal of Pharmacy and Technology 15 (4): 1537-1542. doi: http://dx.doi.org/10.52711/0974-360X.2022.00256
  51. Al-Gubory KsH, Bolifraud P, Germain G, Nicole A, Ceballos-Bicot I (2004) Antioxidant enzymatic defence systems in sheep corpus luteum throughout pregnancy. Reproduction 128 (6): 767-774. doi: https://doi.org/10.1530/rep.1.00389
Cellular, Molecular and Biomedical Reports
Volume 4, Issue 1
Cellular, Molecular and Biomedical Reports (Online ISSN: 2823-2550)
March 2024
Pages 54-64
Files
History
  • Receive Date: 09 May 2023
  • Revise Date: 11 July 2023
  • Accept Date: 20 August 2023
Share
How to cite
Statistics